Table 1

Baseline characteristics

Liraglutide1.8 mg(N = 346)Liraglutide1.2 mg(N = 346)Liraglutide0.6 mg(N = 350)Placebo(N = 347)
Age (years)43.7 ± 13.343.9 ± 13.143.6 ± 12.843.4 ± 12.6
Female sex 181 (52.3)179 (51.7)186 (53.1)180 (51.9)
Duration of type 1 diabetes (years)21.5 ± 12.621.6 ± 12.220.9 ± 12.221.6 ± 11.8
MDI total daily insulin dose (units), geometric mean (CV)62.52 (49.54)59.61 (49.82)59.54 (42.66)62.42 (46.09)
CSII115 (33.2)100 (28.9)71 (20.3)96 (27.7)
CSII total daily insulin dose (units), geometric mean (CV)50.46 (46.31)50.73 (43.87)52.97 (43.74)49.18 (59.94)
Hypoglycemia awareness: yes317 (91.6)326 (94.2)334 (95.4)328 (94.5)
Body weight (kg)86.3 ± 17.385.4 ± 17.286.5 ± 17.386.4 ± 17.8
BMI (kg/m2)29.5 ± 5.229.3 ± 5.129.5 ± 5.329.8 ± 5.6
HbA1c (%)8.14 ± 0.7408.16 ± 0.7798.18 ± 0.7388.15 ± 0.728
HbA1c (mmol/mol)65.5 ± 8.165.7 ± 8.565.9 ± 8.165.5 ± 8.0
(N = 345)(N = 344)(N = 350)(N = 345)
Severe hypoglycemic episode within the last year? Yes25 (7.2)23 (6.7)23 (6.6)28 (8.1)
(N = 341)(N = 340)(N = 343)(N = 340)
FPG (mmol/L)10.01 ± 4.34810.64 ± 4.20510.19 ± 4.2049.96 ± 4.197
(N = 343)(N = 345)(N = 343)(N = 342)
Fasting C-peptide <LLOQ285 (83.1)289 (83.8)269 (78.4)291 (85.1)
  • Values are reported as the mean ± SD or N (%), unless otherwise indicated. CV, coefficient of variation; MDI, multiple dose injection.